---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000068"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:29:38.504826+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Arcutis Biotherapeutics shareholders re-elect three Class II directors, ratify EY, approve say-on-pay

## Summary
- All three Class II directors elected: Heron (44.2M for), Krishnamohan (50.4M for), Watanabe (45.4M for).
- Ratification of Ernst & Young as independent auditor for FY 2023 passed with 54.5M votes for, 358K against.
- Non-binding advisory vote on named executive officer compensation approved with 43.8M for, 7.3M against.
- Meeting held May 31, 2023; record date April 3, 2023 with 61,360,936 shares outstanding.

## SEC filing metadata
- accession: 0001787306-23-000068
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/arqt-20230602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000068
- JSON: https://secwatch.observer/filing/0001787306-23-000068.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000068.txt

## Key facts
- Shareholder Votes
  Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class II directors to hold office until the 2026 annual meeting or until their respective successor is elected at the 2023-05-31 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: Proposal 1. The election of three Class II directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected: Nominee Votes for Votes withheld Broker Non-Votes Patrick J. Heron 44,208,982 6,933,977 3,771,693 Neha Krishnamohan 50,425,906 717,053 3,771,693 Todd Franklin Watanabe 45,416,267 5,726,692 3,771,693
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm
- Shareholder Votes
  Arcutis Biotherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2023-05-31 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: Votes for Votes against Abstentions Broker Non-Votes 43,770,313 7,343,874 28,772 3,771,693
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm
- Shareholder Votes
  Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-31
  source text: Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023: Votes for Votes against Abstentions Broker Non-Votes 54,541,027 358,765 14,860 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000068/0001787306-23-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.